Home  »  Finance   »  New Big Money Means Neurocrine Biosciences Inc. (N...

New Big Money Means Neurocrine Biosciences Inc. (NBIX) Investors Could Reap Benefit

612 institutions hold shares in Neurocrine Biosciences Inc. (NBIX), with 1.07M shares held by insiders accounting for 1.14% while institutional investors hold 99.82% of the company’s shares. The shares outstanding are 93.40M, and float is at 91.22M with Short Float at 6.82%. Institutions hold 98.68% of the Float.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is Janus Henderson Group PLC with over 9.16 million shares valued at $878.1 million. The investor’s holdings represent 9.69% of the NBIX Shares outstanding. As of Dec 30, 2020, the second largest holder is FMR, LLC with 8.36 million shares valued at $801.03 million to account for 8.84% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 8.34 million shares representing 8.82% and valued at over $799.13 million, while Blackrock Inc. holds 7.40% of the shares totaling 7.0 million with a market value of $670.74 million.

Neurocrine Biosciences Inc. (NASDAQ: NBIX) is 1.93% higher on its value in year-to-date trading and has touched a low of $86.02 and a high of $136.26 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NBIX stock was last observed hovering at around $97.68 in the last trading session, with the day’s gains setting it 0.02% off its average median price target of $127.96 for the next 12 months. It is also 40.06% off the consensus price target high of $163.00 offered by 25 analysts, but current levels are 11.18% higher than the price target low of $110.00 for the same period.

Currently trading at $97.70, the stock is 2.20% and -0.30% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.75 million and changing 0.02% at the moment leaves the stock -6.07% off its SMA200. NBIX registered -0.94% loss for a year compared to 6-month gain of -3.21%. The firm has a 50-day simple moving average (SMA 50) of $94.89 and a 200-day simple moving average (SMA200) of $100.01.

The stock witnessed a -3.49% loss in the last 1 month and extending the period to 3 months gives it a -11.82%, and is 0.69% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.61% over the week and 3.22% over the month.

Neurocrine Biosciences Inc. (NBIX) has around 845 employees, a market worth around $9.22B and $1.05B in sales. Current P/E ratio is 23.50 and Fwd P/E is 20.36. Profit margin for the company is 38.90%. Distance from 52-week low is 13.58% and -28.30% from its 52-week high. The company has generated returns on investments over the last 12 months (30.80%).

Neurocrine Biosciences Inc. (NBIX) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Neurocrine Biosciences Inc. (NBIX) is a “Overweight”. 25 analysts offering their recommendations for the stock have an average rating of 2.00, where 8 rate it as a Hold and 2 think it is a “Overweight”. 15 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Neurocrine Biosciences Inc. is expected to release its quarterly report on 08/04/2021 and quarterly earnings per share for the current quarter are estimated at $0.51 with sales reaching $250.63M over the same period.The EPS is expected to grow by 977.20% this year, but quarterly earnings will post 14.40% year-over-year. Quarterly sales are estimated to grow 12.00% in year-over-year returns.

Neurocrine Biosciences Inc. (NBIX) Insider Activity

A total of 83 insider transactions have happened at Neurocrine Biosciences Inc. (NBIX) in the last six months, with sales accounting for 68 and purchases happening 15 times. The most recent transaction is an insider sale by Lloyd-Smith Malcolm, the company’s Chief Regulatory Officer. SEC filings show that Lloyd-Smith Malcolm sold 1,700 shares of the company’s common stock on Feb 10 at a price of $119.96 per share for a total of $0.2 million. Following the sale, the insider now owns 32510.0 shares.

Neurocrine Biosciences Inc. disclosed in a document filed with the SEC on Feb 09 that Lippoldt Darin (Chief Legal Officer) sold a total of 36,194 shares of the company’s common stock. The trade occurred on Feb 09 and was made at $116.17 per share for $4.2 million. Following the transaction, the insider now directly holds 34361.0 shares of the NBIX stock.

Still, SEC filings show that on Feb 08, Lippoldt Darin (Chief Legal Officer) disposed off 3,407 shares at an average price of $116.72 for $0.4 million. The insider now directly holds 31,914 shares of Neurocrine Biosciences Inc. (NBIX).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Neurocrine Biosciences Inc. (NBIX): Who are the competitors?

The company’s main competitors (and peers) include Paratek Pharmaceuticals Inc. (PRTK) that is trading 72.49% up over the past 12 months. CASI Pharmaceuticals Inc. (CASI) is 2.12% up on the 1-year trading charts. Short interest in the company’s stock has fallen -39.78% from the last report on Apr 14, 2021 to stand at a total of 6.22 million short shares sold with a short interest ratio of 3.5.

Related Posts




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam